Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai
Objective We sought to explore the prevalence of type I interferon-neutralizing antibodies in a Chinese cohort and its clinical implications during the Omicron variant wave of SARS-CoV-2. Methods Type I interferon (IFN) autoantibodies possessing neutralizing capabilities were identified using luciferase assays. The capacity of the autoantibodies for in vitro interference with antiviral activity of IFN was assessed by using a SARS-CoV-2 replicon system. An analysis of the demographic and clinical profiles of patients exhibiting neutralizing antibodies was also conducted. Results In this cohort, 11.8% of severe/critical cases exhibited the existence of type I IFN-neutralizing antibodies, specifically targeting IFN-α2, IFN-ω, or both, with an elderly male patient tendency. Notably, these antibodies exerted a pronounced inhibitory effect on the antiviral activity of IFN against SARS-CoV-2 under controlled in vitro conditions. Furthermore, a noteworthy correlation was discerned between the presence of these neutralizing antibodies and critical clinical parameters, including C-reactive protein (CRP) levels, D-dimer levels, and lymphocyte counts. Conclusion The presence of type I IFN-neutralizing antibodies is a pervasive risk factor for severe/critical COVID-19 in the Chinese population..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Journal of clinical immunology - 44(2024), 3 vom: 10. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shi, Dongling [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
COVID-19 |
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1007/s10875-024-01683-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055091598 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055091598 | ||
| 003 | DE-627 | ||
| 005 | 20240424064704.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240311s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10875-024-01683-z |2 doi | |
| 035 | |a (DE-627)SPR055091598 | ||
| 035 | |a (SPR)s10875-024-01683-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.45 |2 bkl | ||
| 100 | 1 | |a Shi, Dongling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Objective We sought to explore the prevalence of type I interferon-neutralizing antibodies in a Chinese cohort and its clinical implications during the Omicron variant wave of SARS-CoV-2. Methods Type I interferon (IFN) autoantibodies possessing neutralizing capabilities were identified using luciferase assays. The capacity of the autoantibodies for in vitro interference with antiviral activity of IFN was assessed by using a SARS-CoV-2 replicon system. An analysis of the demographic and clinical profiles of patients exhibiting neutralizing antibodies was also conducted. Results In this cohort, 11.8% of severe/critical cases exhibited the existence of type I IFN-neutralizing antibodies, specifically targeting IFN-α2, IFN-ω, or both, with an elderly male patient tendency. Notably, these antibodies exerted a pronounced inhibitory effect on the antiviral activity of IFN against SARS-CoV-2 under controlled in vitro conditions. Furthermore, a noteworthy correlation was discerned between the presence of these neutralizing antibodies and critical clinical parameters, including C-reactive protein (CRP) levels, D-dimer levels, and lymphocyte counts. Conclusion The presence of type I IFN-neutralizing antibodies is a pervasive risk factor for severe/critical COVID-19 in the Chinese population. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Type I interferons |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neutralizing antibodies |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a IFN-α2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a IFN-ω |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Chen, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Yuanjia |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Yinpeng |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Di |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Yixin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xuebi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Xiaohong |e verfasserin |4 aut | |
| 700 | 1 | |a Yi, Zhigang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiaohua |e verfasserin |4 aut | |
| 700 | 1 | |a Ling, Yun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical immunology |d Springer US, 1981 |g 44(2024), 3 vom: 10. März |w (DE-627)SPR014233401 |w (DE-600)2016755-6 |x 1573-2592 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:3 |g day:10 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10875-024-01683-z |m X:SPRINGER |x Resolving-System |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.45 |q VZ |
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 3 |b 10 |c 03 | ||